Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 8, 2011, Pages 1193-1196

  Amm, Hope M ^a   Buchsbaum, Donald J ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

breast cancer; galectin 3; triple negative breast cancer; tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

DEATH RECEPTOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALECTIN 3; HISTIDINE; MONOCLONAL ANTIBODY; PROLINE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; BREAST CANCER; CANCER CELL; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; LGALS3 GENE; NOTE; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

EID: 80052313774     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.108     Document Type: Note

References (18)

1. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J. Clin. Oncol. 23, 7350-7360 (2005).
2. Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin. Pharmacol. Ther. 83, 26-36 (2008).
3. Rahman M, Pumphrey JG, Lipkowitz S. The TRAIL to targeted therapy of breast cancer. Adv. Cancer Res. 103, 43-73 (2009).
4. Rahman M, Davis SR, Pumphrey JG et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res. Treat. 113, 217-230 (2009).
5. Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur. J. Cancer. 44, 2799-2805 (2008).
6. Anders CK, Winer EP, Ford JM et al. Poly(ADP-ribose) polymerase inhibition: 'targeted' therapy for triple-negative breast cancer. Clin. Cancer. Res. 16, 4702-4710 (2010).
7. Amm HM, Zhou T, Steg AD, Kuo H, Li Y, Buchsbaum DJ. Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. Mol. Cancer Res. 9, 403-417 (2011).
8. Buchsbaum DJ, Zhou T, Grizzle WE et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 9, 3731-3741 (2003).
9. Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol. Ther. 11, 431-449 (2011).
10. Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer DOI: 10.1002/cncr.26078 (2011) (Epub ahead of print).
11. Dumic J, Dabelic S, Flogel M. Galectin-3: An open-ended story. Biochim. Biophys. Acta 1760, 616-635 (2006).
12. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 57, 5272-5276 (1997).
13. Lee YJ, Song YK, Song JJ et al. Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp. Cell Res. 288, 21-34 (2003).
14. Mazurek N, Sun YJ, Liu KF et al. Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. J. Biol. Chem. 282, 21337-21348 (2007).
15. Balan V, Nangia-Makker P, Schwartz AG et al. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): A pilot study. Cancer Res. 68, 10045-10050 (2008).
16. Mackay A, Jones C, Dexter T et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22, 2680-2688 (2003).
17. Koo JS, Jung W. Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med. J. 52, 89-97 (2011).
18. Cuello M, Ettenberg SA, Clark AS et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand- mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61(Suppl.), 4892-4900 (2001).